Neogen Corp (NEOG) Q3 2026 Earnings Call Transcript

Why It Matters

The earnings beat and margin expansion signal Neogen’s turnaround is gaining traction, positioning the firm for stronger cash generation and debt reduction amid a challenging food‑safety market.

Key Takeaways

• Q2 revenue $224.7M, core growth 2.9% sequential.
• Adjusted EBITDA margin rose to 21.7%, up 470 bps.
• Cost initiatives target $20M annual savings, improving margins.
• Divestiture of cleaners business reduced debt by $100M.
• FY2026 revenue outlook $845‑$855M, EBITDA $175M.

Pulse Analysis

Neogen’s second‑quarter results underscore a decisive shift from the revenue stagnation that plagued the prior year. By leveraging volume‑driven growth in its Food Safety segment—particularly indicator testing and culture media—the company lifted gross margin to 47.5% and adjusted EBITDA margin to a healthy 21.7%. The sequential improvement reflects disciplined cost actions, including headcount reductions and a $20 million annual savings program, which together enhance cash conversion and provide a buffer against lingering macro‑economic headwinds in the food production sector.

Strategic divestitures have also reshaped Neogen’s balance sheet. The sale of the Cleaners and Disinfectants business freed up $100 million to pay down debt, bringing gross debt to $800 million with 68% fixed‑rate exposure. Ongoing efforts to offload the global genomics unit promise additional deleveraging, while the on‑track Petrifilm integration positions the firm to capture higher‑margin sample‑collection revenue later in fiscal 2027. Leadership refreshes—new CFO, chief commercial officer, and senior executives—add operational expertise that is already translating into tighter forecasting, inventory control, and a data‑driven sales cadence.

Looking ahead, Neogen’s raised guidance of $845‑$855 million revenue and $175 million adjusted EBITDA reflects confidence in sustained top‑line momentum despite a cautious outlook for the second half of the year. The company expects routine capex to settle at 3‑4% of revenue, further supporting free‑cash‑flow generation. While macro‑level challenges such as reduced food‑production volumes and animal‑herd declines persist, Neogen’s strategic focus on core diagnostics, margin‑enhancing initiatives, and balance‑sheet strengthening positions it to capitalize on long‑term secular growth in food and animal safety testing. Investors should monitor the progress of the genomics divestiture and the sample‑collection turnaround as key catalysts for continued financial upside.